Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Nutritional High International	Chemesis International	1933 Industries	4Front Ventures	AB Science
Symbol	CNSX:CHAL	CNSX:CSI	OTCMKTS:TGIFF	OTCMKTS:FFNTF	OTCMKTS:ABSCF
Price Information
Current Price	N/A	N/A	$0.06	$1.03	$16.00
50-Day Moving Average	$0.00	$0.00	$0.07	$1.08	$15.86
52-Week Low	$0.00	$0.00	$0.04	$0.50	$8.65
52-Week High	$0.00	$0.00	$0.13	$1.98	$26.70
MarketRank™
Overall Score	1.4	1.0	0.0	0.0	1.0
Analysis Score	2.0	0.0	0.0	0.0	0.0
Community Score	5.0	5.0	0.0	0.0	5.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.0	0.0	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Strong Buy	N/A	N/A	N/A	Buy
Consensus Price Target	$2.46	N/A	N/A	N/A	N/A
% Upside from Price Target	∞ upside	N/A	N/A	N/A	N/A
Trade Information
Market Cap	N/A	N/A	N/A	N/A	N/A
Beta	N/A	N/A	N/A	N/A	N/A
Average Volume	N/A	N/A	722,538	869,910	1,090
Sales & Book Value
Annual Revenue	N/A	N/A	N/A	N/A	N/A
Price / Sales	N/A	N/A	N/A	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	N/A	N/A	N/A	N/A	N/A
Price / Book	N/A	N/A	N/A	N/A	N/A
Profitability
Net Income	N/A	N/A	N/A	N/A	N/A
EPS	N/A	N/A	N/A	N/A	N/A
Trailing P/E Ratio	0.00	0.00	0.00	0.00	0.00
Forward P/E Ratio	N/A	N/A	∞	∞	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	N/A	N/A	N/A	N/A	N/A
Return on Assets (ROA)	N/A	N/A	N/A	N/A	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	N/A
Current Ratio	N/A	N/A	N/A	N/A	N/A
Quick Ratio	N/A	N/A	N/A	N/A	N/A
Ownership Information
Institutional Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Insider Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Miscellaneous
Employees	N/A	147,000	147,000	380	93
Shares Outstanding	N/A	N/A	N/A	N/A	N/A
Next Earnings Date	N/A	N/A	11/29/2021 (Estimated)	11/29/2021 (Estimated)	N/A
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the ... apnews.com - September 23 at 10:24 AM
	AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML) finance.yahoo.com - September 22 at 1:02 PM
	AB Science announced that an abstract on the long-term survival of masitinib in ALS has been ... apnews.com - September 21 at 8:06 AM
	AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology finance.yahoo.com - September 20 at 3:34 PM
	AB Science announced today that it has received authorization to resume patient enrollment in ... apnews.com - September 17 at 9:04 AM
	AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001) finance.yahoo.com - September 16 at 2:58 PM
	AB Science announced that it has received new authorizations to resume patient enrollment in ... apnews.com - September 14 at 12:59 PM
	AB Science announced that it has received new authorizations to resume patient enrollment in ... apnews.com - September 14 at 12:59 PM
	AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib finance.yahoo.com - September 14 at 12:59 PM
	AB Science announced today that results from masitinib study AB12003 in prostate cancer have ... apnews.com - September 14 at 6:50 AM
	AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association finance.yahoo.com - September 13 at 3:42 PM
	AB Science (OTCMKTS:ABSCF) Shares Down 2% americanbankingnews.com - September 9 at 12:56 AM
	AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND finance.yahoo.com - September 2 at 2:37 PM
	AB Science announces that it has received a second authorization to resume patient enrollment, apnews.com - August 25 at 4:44 PM
	AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis finance.yahoo.com - August 25 at 4:44 PM
	AB Science announces that it has received the first authorization to resume patient enrollment ... apnews.com - August 23 at 4:34 PM
	AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the ... apnews.com - August 19 at 5:11 PM
	AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib finance.yahoo.com - August 19 at 5:11 PM
	AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders finance.yahoo.com - August 6 at 5:38 PM
	AB Science announced that results from its Phase 3 AB09004 study on mild to moderate ... apnews.com - July 29 at 1:09 PM
	AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC finance.yahoo.com - July 29 at 1:09 PM
	AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on ... apnews.com - July 22 at 8:04 PM
	AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC) finance.yahoo.com - July 22 at 3:01 PM
	AB Science announces the publication of new survival data showing that masitinib extended ... apnews.com - July 19 at 11:05 PM
	AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib finance.yahoo.com - June 28 at 5:42 PM

Date	Company	Brokerage	Action
5/27/2021	Nutritional High International	Fundamental Research	Initiated Coverage
12/7/2020	AB Science	HC Wainwright	Reiterated Rating
6/30/2020	1933 Industries	Canaccord Genuity	Downgrade
3/30/2020	AB Science	HC Wainwright	Initiated Coverage

(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources